Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Obstetric Labour, Premature; Premature Labor

Treatments: Drug: GSK221149A

Study type: Interventional

Funder types: Industry

Identifiers

NCT00457925

OTA105101

Details and patient eligibility

About

This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.

Sex: Female

Ages: 30 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult, non-smoking females
• Aged between 30 - 55 years old, and BMI of between 19 and 32
• Not of child-bearing potential

Exclusion criteria

• No clinically significant findings on clinical examination, medical examination and blood tests.
• Radiation exposure over previous 3 years is greater than 10mSv
• History of bleeding or gastric problems

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)